Identification of molecular targets and small drug candidates for Huntington's disease via bioinformatics and a network‐based screening approach
Journal of Cellular and Molecular Medicine · 2024-08 · 28 (16)
DOI: 10.1111/jcmm.18588 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 17.08.2024. Verfasst von Md Ridoy Hossain und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Pharmaceutical Biotechnology and Bioinformatics, Department of Genetic Engineering and Biotechnology, Jashore University of Science and…. Hauptthemen laut MEDLINE: Huntington Disease, Computational Biology, Gene Regulatory Networks, Protein Interaction Maps. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Princess Nourah Bint Abdulrahman University, King Saud University.
Abstract (Originalsprache)
Huntington's disease (HD) is a gradually severe neurodegenerative ailment characterised by an increase of a specific trinucleotide repeat sequence (cytosine–adenine–guanine, CAG). It is passed down as a dominant characteristic that worsens over time, creating a significant risk. Despite being monogenetic, the underlying mechanisms as well as biomarkers remain poorly understood. Furthermore, early detection of HD is challenging, and the available diagnostic procedures have low precision and accuracy. The research was conducted to provide knowledge of the biomarkers, pathways and therapeutic targets involved in the molecular processes of HD using informatic based analysis and applying network‐based systems biology approaches. The gene expression profile datasets GSE97100 and GSE74201 relevant to HD were studied. As a consequence, 46 differentially expressed genes (DEGs) were identified. 10 hub genes ( TPM1 , EIF2S3 , CCN2 , ACTN1 , ACTG2 , CCN1 , CSRP1 , EIF1AX , BEX2 and TCEAL5 ) were further differentiated in the protein–protein interaction (PPI) network. These hub genes were typically down‐regulated. Additionally, DEGs‐transcription factors (TFs) connections (e.g. GATA2, YY1 and FOXC1), DEG‐microRNA (miRNA) interactions (e.g. hsa‐miR‐124‐3p and has‐miR‐26b‐5p) were also comprehensively forecast. Additionally, related gene ontology concepts (e.g. sequence‐specific DNA binding and TF activity) connected to DEGs in HD were identified using gene set enrichment analysis (GSEA). Finally, in silico drug design was employed to find candidate drugs for the treatment HD, and while the possible modest therapeutic compounds (e.g. cortistatin A, 13,16‐Epoxy‐25‐hydroxy‐17‐cheilanthen‐19,25‐olide, Hecogenin) against HD were expected. Consequently, the results from this study may give researchers useful resources for the experimental validation of Huntington's diagnosis and therapeutic approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Pharmaceutical Biotechnology and Bioinformatics, Department of Genetic Engineering and Biotechnology, Jashore University of Science and Technology, Jessore, Bangladesh.
- Department of Biosciences, Shifa Tameer-e-Millat University, Islamabad, Pakistan.
- Department of Health Sciences, Novel Global Community Educational Foundation, Hebersham, New South Wales, Australia.
- Department of Pharmacy, Jashore University of Science and Technology, Jessore, Bangladesh.
- Department of Biology, College of Science, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
- Department of Zoology, College of Science, King Saud University, Riyadh, Saudi Arabia.
ORCID-Profile: Md Ridoy Hossain, Partha Biswas
Förderung
- Princess Nourah Bint Abdulrahman University
- King Saud University
Zitieren
APA
Hossain, M. R., Tareq, M. M. I., Biswas, P., Tauhida, S. J., Bibi, S., Zilani, M. N. H., Albadrani, G. M., Al-Ghadi, M. Q., Abdel-Daim, M. M., & Hasan, M. N. (2024). Identification of molecular targets and small drug candidates for Huntington's disease via bioinformatics and a network‐based screening approach. Journal of Cellular and Molecular Medicine, 28(16). https://doi.org/10.1111/jcmm.18588
Vancouver
Hossain MR, Tareq MMI, Biswas P, Tauhida SJ, Bibi S, Zilani MNH, et al. Identification of molecular targets and small drug candidates for Huntington's disease via bioinformatics and a network‐based screening approach. Journal of Cellular and Molecular Medicine. 2024;28(16). doi:10.1111/jcmm.18588
BibTeX
@article{Hossain2024,
author = {Hossain, Md Ridoy and Tareq, Md Mohaimenul Islam and Biswas, Partha and Tauhida, Sadia Jannat and Bibi, Shabana and Zilani, Md Nazmul Hasan and Albadrani, Ghadeer M and Al-Ghadi, Muath Q and Abdel-Daim, Mohamed M and Hasan, Md Nazmul},
title = {Identification of molecular targets and small drug candidates for Huntington's disease via bioinformatics and a network‐based screening approach},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
volume = {28},
number = {16},
doi = {10.1111/jcmm.18588}
}
EUVIMED